Q2 2024 Ascelia Pharma AB Earnings Call Transcript
Key Points
- Ascelia Pharma AB (FRA:7ZA) completed the pivotal Phase 3 clinical study for Orviglance, marking a significant milestone in the company's history.
- Orviglance has orphan drug designation from the FDA and targets an $800 million annual market opportunity.
- The SPARKLE Phase 3 study demonstrated strong superior enhancement of liver lesion visualization with Orviglance compared to unenhanced MRI.
- The company has secured a rights issue to raise up to SEK105 million, with SEK70 million guaranteed, to finance key milestones.
- Oncoral, another drug in the pipeline, is ready to start Phase 2 trials for gastric cancer, showing promising results from Phase 1.
- Ascelia Pharma AB (FRA:7ZA) reported an operating loss of SEK11.3 million in Q2 2024.
- The company's share price has declined by 92% over the past three years, raising concerns among shareholders.
- There are potential risks and delays associated with the pre-submission meeting with the FDA for Orviglance.
- The company faces challenges in securing commercialization partnerships for Orviglance.
- Intra-reader variability issues during the first readout process could pose challenges in discussions with partners and the FDA.
Welcome, everyone, to the webcast for Ascelia Pharma's Q2 report for 2024. So we will be making forward-looking statements. On today's call, we will start with the Ascelia Pharma highlights and recent key events. This is followed by a portfolio update before moving to financials and priorities ahead.
(Operator Instructions)
At Ascelia Pharma, we identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. Orviglance has now been advanced to registration phase as we have completed the pivotal Phase 3 clinical study. Orviglance has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million annually.
Oncoral is ready to start Phase 2 in the treatment of gastric cancer based on encouraging results in Phase 1 and a high level of unmet medical need. We are based in Malmo, Sweden, and are listed on NASDAQ Stockholm.
Q2 was a remarkable quarter where we met the most significant
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
